Ignite Creation Date:
2024-05-05 @ 4:39 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00285597
Status:
UNKNOWN
Last Update Posted:
2009-10-09
First Post:
2006-01-31
Brief Title:
Ursodeoxycholic Acid in Chronic Heart Failure
Sponsor:
National Heart and Lung Institute
Organization:
National Heart and Lung Institute
Study Overview
Official Title:
Ursodeoxycholic Acid Therapy in Chronic Heart Failure A Placebo-controlled Study Evaluating the Effects of Ursodeoxycholic Acid on Peripheral Blood Flow and Immune Function
Status:
UNKNOWN
Status Verified Date:
2009-10
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a double-blind placebo-controlled cross-over study evaluating the effects of UDCA on peripheral blood flow and immune function in patients with stable chronic heart failure CHF Sixteen patients with CHF will be recruited from the heart failure clinic at the Royal Brompton Hospital Following baseline evaluation patients will be randomised to receive either placebo or UDCA at a dose of 1000 mgday for a period of four weeks They will then undergo repeat evaluation peripheral blood flow and immune function A four week washout period will then take place before the patients cross-over to receive the respective other therapy for a further four weeks ie those first receiving placebo will go onto receive UDCA and vice versa The study will be completed after a total of twelve weeks with a final assessment peripheral blood flow and immune function
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None